255 related articles for article (PubMed ID: 27264163)
1. The economic burden of spinal muscular atrophy.
Armstrong EP; Malone DC; Yeh WS; Dahl GJ; Lee RL; Sicignano N
J Med Econ; 2016 Aug; 19(8):822-6. PubMed ID: 27264163
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
3. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
[TBL] [Abstract][Full Text] [Related]
4. Disease burden of spinal muscular atrophy in Germany.
Klug C; Schreiber-Katz O; Thiele S; Schorling E; Zowe J; Reilich P; Walter MC; Nagels KH
Orphanet J Rare Dis; 2016 May; 11(1):58. PubMed ID: 27145956
[TBL] [Abstract][Full Text] [Related]
5. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain.
López-Bastida J; Peña-Longobardo LM; Aranda-Reneo I; Tizzano E; Sefton M; Oliva-Moreno J
Orphanet J Rare Dis; 2017 Aug; 12(1):141. PubMed ID: 28821278
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of brain metastasis among lung cancer patients in the United States.
Guérin A; Sasane M; Dea K; Zhang J; Culver K; Nitulescu R; Wu EQ; Macalalad AR
J Med Econ; 2016; 19(5):526-36. PubMed ID: 26735844
[TBL] [Abstract][Full Text] [Related]
7. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data.
Chan SHS; Wong CKH; Wu T; Wong W; Yu MKL; Au ICH; Chan GCF
Eur J Health Econ; 2023 Nov; 24(8):1373-1382. PubMed ID: 36403177
[TBL] [Abstract][Full Text] [Related]
8. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population.
Lee S; Xie L; Wang Y; Vaidya N; Baser O
J Med Econ; 2018 Jun; 21(6):564-570. PubMed ID: 29359606
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada.
Chen G; Sharif B; Gerber B; Farris MS; Cowling T; Cabalteja C; Wu JW; Maturi B; Klein-Panneton K; Jean K Mah
J Med Econ; 2021 Nov; 24(sup1):51-59. PubMed ID: 34906030
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
12. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants.
Shi N; Palmer L; Chu BC; Katkin JP; Hall CB; Masaquel AS; Mahadevia PJ
J Med Econ; 2011; 14(3):335-40. PubMed ID: 21524154
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Adult Patients With SMA Treated in US Hospital Settings: A Natural History Study in the Premier Healthcare Database.
Johnson NB; Proud C; Wassel CL; Dreyfus J; Cochrane T; Paradis AD
J Neuromuscul Dis; 2021; 8(4):569-578. PubMed ID: 33843692
[TBL] [Abstract][Full Text] [Related]
14. One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
Burton TM; Lacey M; Liu F; Yu Y; Monsalvo ML; Lang K; Sander S
J Med Econ; 2012; 15(6):1217-25. PubMed ID: 22857539
[TBL] [Abstract][Full Text] [Related]
15. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
[TBL] [Abstract][Full Text] [Related]
16. Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma.
Song X; Liu Z; Cappell K; Gregory C; Said Q; Prestifilippo J; Charles H; Hulbert J; Bissler J
J Med Econ; 2017 Apr; 20(4):388-394. PubMed ID: 27998195
[TBL] [Abstract][Full Text] [Related]
17. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
Rothbard AB; Lee S; Blank MB
J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
[TBL] [Abstract][Full Text] [Related]
18. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
19. Low-intensity pulsed ultrasound (LIPUS) can decrease the economic burden of fracture non-union.
Mehta S; Long K; DeKoven M; Smith E; Steen RG
J Med Econ; 2015; 18(7):542-9. PubMed ID: 25708448
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
